Immunocore Holdings PLC

자세한 내용은 Immunocore Holdings PLC 회사

Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.

회사 정보

종목 코드 IMCR

회사 이름Immunocore Holdings PLC

상장일Feb 05, 2021

CEODr. Bahija Jallal, Ph.D.

직원 수493

유형Depository Receipt

회계 연도 종료Feb 05

주소92 Park Drive Milton Park

도시ABINGDON

증권 거래소NASDAQ Global Select Consolidated

국가United Kingdom

우편 번호OX14 4RY

전화441235438600

웹사이트https://www.immunocore.com/

종목 코드 IMCR

상장일Feb 05, 2021

CEODr. Bahija Jallal, Ph.D.

회사 임원

이름

이름/직위

직위

주식 보유

변동

Prof. John Bell

Independent Chairman of the Board

13.45K

--

Mr. Roy S. Herbst, M.D., Ph.D.

Non-Executive Independent Director

--

Mr. Clayton Robertson

Head of Investor Relations

--

Dr. Bahija Jallal, Ph.D.

Chief Executive Officer, Executive Director

--

Ms. Tina St. Leger

Chief Human Resources Officer

--

Dr. William Pao, M.D., Ph.D.

Non-Executive Independent Director

--

Mr. Ranjeev Krishana

Non-Executive Independent Director

--

Mr. Siddharth Kaul

Non-Executive Independent Director

--

Ms. Kristine Peterson

Non-Executive Independent Director

--

Prof. Peter Ratcliffe

Non-Executive Independent Director

--

이름

이름/직위

직위

주식 보유

변동

Prof. John Bell

Independent Chairman of the Board

13.45K

--

Mr. Roy S. Herbst, M.D., Ph.D.

Non-Executive Independent Director

--

Mr. Clayton Robertson

Head of Investor Relations

--

Dr. Bahija Jallal, Ph.D.

Chief Executive Officer, Executive Director

--

Ms. Tina St. Leger

Chief Human Resources Officer

--

Dr. William Pao, M.D., Ph.D.

Non-Executive Independent Director

--

수익 분석

통화: USD마지막 업데이트: Sun, Jul 6

FY2024

FY2023

FY2023Q3

FY2023Q2

FY2022

FY2022Q3

FY2022Q2

FY2020

FY2019

데이터 없음

지역별USD

이름

수익

비율

United States

226.69M

73.08%

Europe

73.22M

23.61%

International

10.08M

3.25%

Collaboration revenue

213.00K

0.07%

사업별

지역별

데이터 없음

주식 보유 통계

마지막 업데이트: Sat, May 17

주주

주주 유형

주주

비율

T. Rowe Price Investment Management, Inc.

14.25%

Wellington Management Company, LLP

12.39%

RTW Investments L.P.

9.84%

Fidelity Management & Research Company LLC

9.71%

PRIMECAP Management Company

5.41%

Other

48.41%

주주

비율

T. Rowe Price Investment Management, Inc.

14.25%

Wellington Management Company, LLP

12.39%

RTW Investments L.P.

9.84%

Fidelity Management & Research Company LLC

9.71%

PRIMECAP Management Company

5.41%

Other

48.41%

주주 유형

주주

비율

Investment Advisor

41.30%

Investment Advisor/Hedge Fund

26.52%

Hedge Fund

22.94%

Corporation

5.15%

Private Equity

3.16%

Research Firm

2.66%

Pension Fund

0.42%

Bank and Trust

0.25%

Venture Capital

0.04%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

292

50.72M

102.46%

-9.05M

2025Q1

304

50.82M

102.67%

-9.36M

2024Q4

304

48.99M

99.30%

-7.33M

2024Q3

299

49.26M

99.94%

-5.38M

2024Q2

298

47.15M

96.58%

+1.62M

2024Q1

283

47.77M

97.93%

+3.51M

2023Q4

262

40.76M

86.07%

-2.70M

2023Q3

246

44.95M

95.97%

-1.86M

2023Q2

236

43.68M

94.12%

-435.38K

2023Q1

218

40.62M

88.44%

-3.40M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

T. Rowe Price Investment Management, Inc.

7.05M

14.25%

+351.61K

+5.25%

Mar 31, 2025

Wellington Management Company, LLP

6.13M

12.39%

-485.33K

-7.33%

Mar 31, 2025

RTW Investments L.P.

4.87M

9.84%

--

Mar 31, 2025

Fidelity Management & Research Company LLC

4.81M

9.71%

+23.88K

+0.50%

Mar 31, 2025

PRIMECAP Management Company

2.68M

5.41%

+10.10K

+0.38%

Mar 31, 2025

Eli Lilly Vostok SA Geneva

2.55M

5.15%

--

Mar 21, 2025

Baker Bros. Advisors LP

2.32M

4.69%

+807.34K

+53.28%

Mar 31, 2025

Tang Capital Management, LLC

1.92M

3.87%

+360.11K

+23.15%

Mar 31, 2025

T. Rowe Price Associates, Inc.

1.89M

3.81%

-299.59K

-13.70%

Mar 31, 2025

Kynam Capital Management LP

1.70M

3.43%

+470.00K

+38.35%

Mar 31, 2025

33.015USD

Immunocore Holdings PLC

33.015

개요

회사

금융